Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

Blood

Volumn 118, Issue 23, 2011, Pages 6030-6036

  Löwenberg, Bob ^a   Muus, Petra ^b   Ossenkoppele, Gert ^c   Rousselot, Philippe ^d   Cahn, Jean Yves ^e   Ifrah, Norbert ^f   Martinelli, Giovanni ^g   Amadori, Sergio ^h   Berman, Ellin ⁱ   Sonneveld, Pieter ^a   Jongen Lavrencic, Mojca ^a   Rigaudeau, Sophie ^d   Stockman, Paul ^j   Goudie, Alison ^j   Faderl, Stefan ^k   Jabbour, Elias ^k   Kantarjian, Hagop ^k  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d CENTRE HOSPITALIER DE VERSAILLES   (France)

^e Clinique Universitaire d'Hématologie   (France)

^f ANGERS UNIVERSITY HOSPITAL   (France)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j ASTRAZENECA   (United Kingdom)

^k UNIVERSITY OF TEXAS   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BARASERTIB;

ACUTE CHOLECYSTITIS; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALOPECIA; ARTICLE; CELLULITIS; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; STOMATITIS; SWELLING; TREATMENT RESPONSE;

EID: 82955217793     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-07-366930     Document Type: Article

References (34)

1. Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341(14):1051-1062. (Pubitemid 29451802)
2. Löwenberg B, Griffin JD, Tallman MS. Acute myeloid leukemia and acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program. 2003:82-101.
3. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol. 2007;25(14):1908-1915. (Pubitemid 46854425)
4. Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487-494.
5. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study. Blood. 1997;89(9):3323-3329.
6. Meraldi P, Honda R, Nigg EA. Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Genet Dev. 2004;14(1):29-36. (Pubitemid 38167474)
7. Mistry HB, MacCallum DE, Jackson RC, Chaplain MA, Davidson FA. Modeling the temporal evolution of the spindle assembly checkpoint and role of Aurora B kinase. Proc Natl Acad Sci U S A. 2008;105(51):20215-20220.
8. Andrews PD. Aurora kinases: shining lights on the therapeutic horizon? Oncogene. 2005;24(32):5005-5015. (Pubitemid 41129079)
9. Ota T, Suto S, Katayama H, et al. Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res. 2002;62(18):5168-5177. (Pubitemid 35024587)
10. Kanda A, Kawai H, Suto S, et al. Aurora-B/AIM-1 kinase activity is involved in Ras-mediated cell transformation. Oncogene. 2005;24(49):7266-7272. (Pubitemid 41622230)
11. Walsby E, Walsh V, Pepper C, Burnett A, Mills K. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Haematologica. 2008;93(5):662-669. (Pubitemid 351669305)
12. Oke A, Pearce D, Wilkinson RW, et al. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Cancer Res. 2009;69(10):4150-4158.
13. Joel SP, Oke A, Foot N, et al. The activity of the novel Aurora Kinase B inhibitor AZD1152 in acute myeloid leukaemia cells [abstract]. Blood. 2005;106(11):3374.
14. Tomita M, Tanaka Y, Mori N. Aurora kinase inhibitor AZD1152 negatively affects the growth and survival of HTLV-1-infected T lymphocytes in vitro. Int J Cancer. 2010;127(7):1584-1594.
15. Ikezoe T, Takeuchi T, Yang J, et al. Analysis of Aurora B kinase in non-Hodgkin lymphoma. Lab Invest. 2009;89(12):1364-1373.
16. Wilkinson RW, Odedra R, Heaton SP, et al. AZD1152, a selective inhibitor of aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res. 2007;13(12):3682-3688. (Pubitemid 46955132)
17. Boss DS, Witteveen PO, van der Sar J, et al. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann Oncol. 2011;22(2):431-437.
18. Cohen RB, Jones SF, Aggarwal C, et al. A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res. 2009;15(21):6694-6701.
19. Steeghs N, Eskens FA, Gelderblom H, et al. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J Clin Oncol. 2009;27(30):5094-5101.
20. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-4649. (Pubitemid 46594039)
21. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17(8):857-872. (Pubitemid 28185165)
22. Grimwade D, Hills RK. Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Educ Program. 2009:385-395.
23. Jones SF, Burris HA, III, Dumez H, et al. Phase I accelerated dose-escalation, pharmacokinetic (PK) and pharmacodynamic study of PF-03814735, an oral aurora kinase inhibitor, in patients with advanced solid tumors: preliminary results [abstract]. J Clin Oncol. 2008;26(15 suppl):2517.
24. Plummer ER, Calvert H, Arkenau H, et al. A dose-escalation and pharmacodynamic study of AT9283 in patients with refractory solid tumours [abstract]. J Clin Oncol. 2008;26(15 suppl):2519.
25. Renshaw JS, Patnaik A, Gordon M, et al. A phase I two arm trial of AS703569 (R763), an orally available aurora kinase inhibitor, in subjects with solid tumors: preliminary results [abstract]. J Clin Oncol. 2007;25(18 suppl):14130.
26. Robert F, Hurwitz H, Verschraegen CF, et al. Phase 1 trial of SNS-314, a novel selective inhibitor of aurora kinases A, B, and C, in advanced solid tumor patients [abstract]. J Clin Oncol. 2008;26(15 suppl):14642.
27. Dees EC, Infante JR, Burris HA, et al. Phase I study of the investigational drug MLN8237, an Aurora A kinase (AAK) inhibitor, in patients (pts) with solid tumors [abstract]. J Clin Oncol. 2010;28(15 suppl):3010.
28. de Jonge M, Steeghs N, Verweij J, et al. Phase I study of the aurora kinases (AKs) inhibitor PHA-739358 administered as a 6 and 3-h IV infusion on Days 1, 8, 15 every 4 wks in patients with advanced solid tumors [abstract]. J Clin Oncol. 2008;26(15 suppl):3507.
29. Cohen RB, Jones SF, von Mehren M, et al. Phase I study of the pan aurora kinases (AKs) inhibitor PHA-739358 administered as a 24 h infusion without/with G-CSF in a 14-day cycle in patients with advanced solid tumors [abstract]. J Clin Oncol. 2008;26(15 suppl):2520.
30. Howard S, Berdini V, Boulstridge JA, et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem. 2009;52(2):379-388.
31. Foran JM, Ravandi F, O'Brien SM, et al. Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia [abstract]. J Clin Oncol. 2008;26(15 suppl):2518.
32. Sonet A, Graux C, Maertens J, et al. Phase I, dose-escalation study of 2 dosing regimens of AS703569, an inhibitor of aurora and other kinases, administered orally in patients with advanced hematological malignancies [abstract]. Blood. 2008;112(11):2963.
33. Keen N, Brown E, Crafter C, et al. Biological characterisation of AZD1152, a highly potent and selective inhibitor of aurora kinase activity [abstract]. Clin Cancer Res. 2005;11:B220.
34. Kantarjian HM, Sekeres MA, Ribrag V, et al. Phase I study to assess the safety and tolerability of AZD1152 in combination with low dose cytosine arabinoside in patients with acute myeloid leukemia (AML) [abstract]. Blood. 2010;116(21):656.